Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Study Summary

This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.

Conditions

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Interventions / Drugs

ALLO-316 ALLO-647 Fludarabine Cyclophosphamide

View on ClinicalTrials.gov ↗

Sponsor

ALLO

Allogene Therapeutics

Cell Therapy

C55/100

Study Details

Enrollment120 participants

Primary Completion—

Lead SponsorAllogene Therapeutics

Data Retrieved2026-04-11 02:53:23.198044+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.